BridgeBio have substantially improved the development of a novel therapy for ATTR-CM, employing the investigational drug. Preliminary trial data reveals potential improvements for those suffering with the severe https://biotech730882.theisblog.com/42551904/bridgebio-progresses-cardiac-amyloidosis-therapy-through-the-therapy